Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Current Assets: 2016-2025

Historic Current Assets for Akebia Therapeutics (AKBA) over the last 10 years, with Sep 2025 value amounting to $258.3 million.

  • Akebia Therapeutics' Current Assets rose 158.03% to $258.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.3 million, marking a year-over-year increase of 158.03%. This contributed to the annual value of $113.8 million for FY2024, which is 3.65% down from last year.
  • Per Akebia Therapeutics' latest filing, its Current Assets stood at $258.3 million for Q3 2025, which was up 10.09% from $234.7 million recorded in Q2 2025.
  • Akebia Therapeutics' Current Assets' 5-year high stood at $365.0 million during Q1 2021, with a 5-year trough of $100.1 million in Q3 2024.
  • Over the past 3 years, Akebia Therapeutics' median Current Assets value was $118.1 million (recorded in 2023), while the average stood at $145.7 million.
  • Its Current Assets has fluctuated over the past 5 years, first slumped by 61.57% in 2023, then soared by 158.03% in 2025.
  • Over the past 5 years, Akebia Therapeutics' Current Assets (Quarterly) stood at $271.1 million in 2021, then crashed by 31.70% to $185.2 million in 2022, then tumbled by 36.20% to $118.1 million in 2023, then dropped by 3.65% to $113.8 million in 2024, then surged by 158.03% to $258.3 million in 2025.
  • Its Current Assets was $258.3 million in Q3 2025, compared to $234.7 million in Q2 2025 and $203.8 million in Q1 2025.